Safety of using glucagon-like peptide-1 receptor agonists before gastrointestinal endoscopy：an overview of systematic reviews
- VernacularTitle:消化道内镜检查前使用胰高血糖素样肽1受体激动剂的安全性系统评价再评价
- Author:
Yuzhou LI
1
;
Shuying ZOU
2
;
Xiangnan ZHU
1
;
Li TANG
1
;
Peng LI
3
;
Caixia XIE
3
Author Information
1. School of Medicine，University of Electronic Science and Technology of China，Chengdu 610054，China
2. College of Nursing，Chengdu University of TCM，Chengdu 610075，China
3. Anesthesia and Surgery Center，Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital （Affiliated Hospital of UESTC），Chengdu 610072，China
- Publication Type:Journal Article
- Keywords:
glucagon-like peptide-1 receptor agonists;
gastrointestinal endoscopy;
safety;
overview of systematic reviews
- From:
China Pharmacy
2026;37(6):806-811
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To conduct a systematic review concerning the safety of using glucagon-like peptide-1 receptor agonists （GLP-1RA） before gastrointestinal endoscopy. METHODS Chinese and English databases including CNKI， Wanfang Data， VIP， CBM， and PubMed were searched to collect systematic reviews and meta-analyses on the safety of using GLP-1RA before gastrointestinal endoscopy， with a search period from the inception to September 30， 2025. Report quality， methodological quality， risk of bias， and evidence quality were assessed using the PRISMA 2020 statement， AMSTAR 2 scale， ROBIS tool， and GRADE tool， respectively. Corrected covered area （CCA） was used to quantitatively evaluate the degree of outcome overlap， and a comprehensive quality analysis was performed on the quantitative results of systematic reviews/meta-analyses. RESULTS Ten studies were included. All 10 stu dies had some information deficiencies （15.5-19.5 points）， and were at high risk of bias； 9 studies were extremely low methodological quality， while 1 study was low. In terms of evidence quality， among 88 outcome indexes， there was 1 moderate-level index， 28 low-level indexes， and 59 extremely low-level indexes. The CCA values of the incidence of residual gastric contents， aspiration， endoscopy interruption， repeated endoscopy， inadequate bowel preparation and Boston Bowel Preparation Scale scores were 37.30%， 35.00%， 35.00%， 50.00%， 29.60% and 20.00%， respectively. Results of comprehensive quality analysis showed that compared with the control group， the incidence of residual gastric contents， endoscopy interruption and repeated endoscopy were increased significantly in the intervention group， along with a notably prolonged gastric emptying time and a significantly lower score of Boston Bowel Preparation Scale （ P ＜0.05）. However， the study results regarding the effects of GLP-1RA on the incidence of aspiration and inadequate bowel preparation were inconsistent. CONCLUSIONS The use of GLP-1RA before gastrointestinal endoscopy can increase certain safety risks， including residual gastric contents， endoscopy interruption and repeated endoscopy， prolong gastric emptying time， and reduce the quality of bowel preparation. However， the effects on aspiration and inadequate bowel preparation remain controversial. The reports included in systematic reviews/meta-analyses exhibited low quality in reporting， methodology and evidence， with high risk of bias. Therefore， conclusions should be interpreted with caution.
